lumacaftor 200 mg q12h + ivacaftor 250 mg q12h
VX13-809-010
Phase 1 small_molecule completed
Quick answer
lumacaftor 200 mg q12h + ivacaftor 250 mg q12h for Hepatic Impairment is a Phase 1 program (small_molecule) at VERTEX PHARMACEUTICALS INC / MA with 1 ClinicalTrials.gov record(s).
Program details
- Company
- VERTEX PHARMACEUTICALS INC / MA
- Indication
- Hepatic Impairment
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed